Terms ending in 2041
Every in-force patent on Biogen Ma Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,897,898 | Pyridine Macrocycle Compounds as ASK1 Inhibiting Agents In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 11,850,232 | Drug for Treating or Preventing Cerebral Hemorrhage, and Method for Treating or Preventing Cerebral Hemorrhage Using the Drug In force · High confidence | Corxel Pharmaceuticals Hong Kong Limited | In force | High confidence | |
| US 12,162,952 | Human-Derived Anti-(POLY-GA) Dipeptide Repeat (DPR) Antibody In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 12,685,851 | Fluid Catheter Device for Recording Brain State In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 11,999,715 | ASK1 Inhibiting Agents In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 12,138,244 | Drug and Method of Treating or Preventing Renal Disease Using Drug In force · High confidence | Showa Medical University | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Biogen Ma Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.